|
|
Article: Abraxis BioScience Announces Agreement with Green Cross Corporation for the Commercialization of ABRAXANE in Korea.
- Article from:
- Business Wire
- Article date:
- November 27, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Abraxis Also to License Five Biosimilar Products
LOS ANGELES -- Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced that it has granted an exclusive license to Green Cross Corporation for the commercialization of ABRAXANE([R])(paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in Korea. Through this agreement, Green Cross will pay a royalty on net sales of ABRAXANE in Korea as well as upfront and milestone payments.
Green Cross is responsible for the commercialization of ABRAXANE in Korea and will employ an exclusive sales force following regulatory and pricing approval for ABRAXANE ...